Evidence map›Paper›PMID 36721630›Full record

ArticleInfection and drug resistance2023

Screening and Drug Resistance Analysis of Non-Tuberculous Mycobacteria in Patients with Suspected Pulmonary Tuberculosis on the Hainan Island, China.

Jieying Wang, Zhuolin Chen, Yuni Xu, Wenhua Qiu, Shaowen Chen, Hua Pei, Yeteng Zhong

Open access · goldAbstract read
In one paragraph

Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Genome and drug resistance analysis ofFrontiers in microbiology · 2026
    Article
  6. Comments on "Journal of clinical tuberculosis and other mycobacterial diseases · 2025
    Article
  7. Article
  8. Comparison of molecular testing methods for diagnosing non-tuberculous mycobacterial infections.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jieying Wang *Department of Clinical Laboratory, The Second Affiliated Hospital of Hainan Medical University, Haikou, People's Republic of China.
Zhuolin Chen *Department of Clinical Laboratory, The Second Affiliated Hospital of Hainan Medical University, Haikou, People's Republic of China.
Yuni XuDepartment of Clinical Laboratory, The Second Affiliated Hospital of Hainan Medical University, Haikou, People's Republic of China.
Wenhua QiuDepartment of Clinical Laboratory, The Second Affiliated Hospital of Hainan Medical University, Haikou, People's Republic of China.
Shaowen ChenDepartment of Clinical Laboratory, The Second Affiliated Hospital of Hainan Medical University, Haikou, People's Republic of China.
Hua PeiDepartment of Clinical Laboratory, The Second Affiliated Hospital of Hainan Medical University, Haikou, People's Republic of China.
Yeteng ZhongDepartment of Clinical Laboratory, The Second Affiliated Hospital of Hainan Medical University, Haikou, People's Republic of China.ORCID 0000-0002-3584-5391
Hainan Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: China has seen a drastic increase in the incidence of non-tuberculous mycobacteria (NTM) infection, which is a notable public health issue. Due to a lack of reliable epidemiological surveillance information, there is a need to gather accurate epidemiological and surveillance data, which can help clinicians effectively treat NTM patients. Moreover, drug susceptibility testing for NTM is not frequently performed in China. This retrospective study, therefore, determined the prevalence and resistance characteristics of NTM to provide a reference to control the NTM epidemic. Methods: Sputum, alveolar lavage fluid, and other respiratory specimens were collected from 3025 patients with suspected pulmonary tuberculosis attending The Second Affiliated Hospital of Hainan Medical University from January 2014 to December 2021. Strain identification and species distribution of NTM were performed by DNA chip technology and gene sequencing, and the drug resistance of NTM isolates was evaluated by calculating the minimum inhibitory concentration through antimicrobial susceptibility testing for NTM. Results: From 2014 to 2021, 373 strains of NTM were isolated and identified from respiratory specimens of 3025 suspected tuberculosis patients. Except in 2014, NTM-infected patients accounted for more than 10% of suspected tuberculosis patients in other years. The median age of patients with NTM infection was 62.0 years (53.0, 71.0), and the male-to-female ratio among these patients was 0.79:1. Among culture-positive strains, 12.3% (373/3040; 95% CI 11.1-13.4%) were identified as NTM comprising forty species of NTM. The forty species of NTM included 23 slow-growing mycobacteria (SGM) and 17 rapidly-growing mycobacteria (RGM). Among the NTM isolates, 58.7% (219/373; 95% CI 53.7-63.7%) were SGM and 41.3% (154/373; 95% CI 36.3-46.3%) were RGM. Conclusion: During 2014-2021, the number of NTM isolates detected in the respiratory specimens of the study patients in The Second Affiliated Hospital of Hainan Medical University increased year by year.

Indexed as

drug resistanceMycobacteriumnon-tuberculous mycobacteriapulmonary disease

Identifiers

PMID36721630
PMCPMC9884444
OpenAlexW4318753862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.